Are Rio Tinto Limited and Cochlear Limited buying opportunities?

What do a hearing device maker and a big iron ore miner have in common?

They both have cycles of business that an investor can use to their advantage. Rather than chasing high prices when Rio Tinto Limited (ASX: RIO) and Cochlear Limited (ASX: COH) are popular, you can get a bigger bang for your long-term buck when the outlook seems gloomy.

The ongoing woes of the iron ore market seem set to continue, yet Rio Tinto hasn’t fallen that much in price recently. Looking past the regular price rises that can occur before the August results season, the stock has moved down from about $63 in mid-July to its current $61.66, or about 2.1%.

The stock really hasn’t been punished severely despite the very bearish news of iron ore prices at five-year lows. Why? The lowest cost producers survive. Rio has deep pockets to stretch things out much longer.

I’m not an incredible fan of mining stocks in general, but when they are at cyclical lows, you should be at least sharpening your pencil to see which companies will come out on top at the “iron ore hunger games”.

This is classic cyclical movement, so longer-term investors can take advantage of market weakness.

Rio has a 9.8 price-earnings ratio, towards the lower end of its past PE averages. Scaling into a position is the way to go if you are interested in mining stocks.

Cochlear, the hearing aid and bionic ear device maker, is on the rise since bringing new devices onto the market recently. The devices are hi-tech and command a premium in pricing, way different from iron ore, but the company rises and falls on the development of new products.

That’s why the stock still has legs even though it hit a new 52-week high of $73.32 at the start of September. Some customer demand was previously held up because they were waiting for the new products to come out. Now that they are, that pent-up demand will flow through the top and bottom line over the next 6 – 12 months.

The stock shot up from about $64 when its FY 2014 full year results were announced, even though earnings were way down. It is settling back down to that price range once more.

It has a 36 price-earnings ratio, so it’s not cheap. That is at the top of its past PE range. Still, analyst consensus forecasts have earnings potentially doubling by 2017.

Although both offer interesting prospects, I am not drawn strongly to either. I would lean toward Cochlear because it is in the healthcare space, but it is still dependent on product releases and manufacturing issues.

Now if you are looking for a growing stock with a big dividend to buy right now, The Motley Fool’s top analyst, Scott Phillips, may have found it for you. Recently identified as a cheap but growing ASX stock with a 6.6% grossed-up dividend yield, this company has been dubbed the “Top Dividend Stock for 2014-2015” . If you’re interested in knowing its name, just click on the link below, enter your email address and you’ll be sent the FREE report on his top dividend stock idea for 2014 – 2015!

Discover our top dividend stock for 2014-2015

Every year, Motley Fool investment advisor Scott Phillips hand-picks 1 ASX dividend stock with outstanding potential. Just click here to download your free copy of "The Motley Fool's Top Dividend Stock for 2014-2015" today.

Motley Fool contributor Darryl Daté-Shappard does not own shares in any company mentioned. 

Two New Stock Picks Every Month!

Not to alarm you, but you’re about to miss a very important event! Chief Investment Advisor Scott Phillips and his team at Motley Fool Share Advisor are about to reveal their latest official stock recommendation. The premium “buy alert” will be unveiled to members and you can be among the first to act on the tip.

Don’t let this opportunity pass you by – this is your chance to get in early!

Simply enter your email now to find out how you can get instant access.

By clicking this button, you agree to our Terms of Service and Privacy Policy. We will use your email address only to keep you informed about updates to our website and about other products and services we think might interest you. You can unsubscribe from Take Stock at anytime. Please refer to our Financial Services Guide (FSG) for more information.